Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 102-109
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.102
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.102
Comparative study between Embosphere® and Marine gel® as embolic agents for chemoembolization of hepatocellular carcinoma
Hyo-Cheol Kim, Jin Woo Choi, Department of Radiology, Seoul National University Hospital, Seoul 03080, South Korea
Author contributions: Kim HC designed the research study and performed the research; Kim HC and Choi JW analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Seoul National University Hospital.
Informed consent statement: The informed consent was waived by the institutional review board.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hyo-Cheol Kim, MD, Professor, Department of Radiology, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul 03080, South Korea. radioembolization@snu.ac.kr
Received: September 3, 2023
Peer-review started: September 3, 2023
First decision: October 30, 2023
Revised: November 12, 2023
Accepted: December 8, 2023
Article in press: December 8, 2023
Published online: January 15, 2024
Peer-review started: September 3, 2023
First decision: October 30, 2023
Revised: November 12, 2023
Accepted: December 8, 2023
Article in press: December 8, 2023
Published online: January 15, 2024
Core Tip
Core Tip: Conventional chemoembolization, a main treatment option for unresectable hepatocellular carcinoma (HCC), involves delivery of anticancer drug and embolic materials. The current study aimed to assess the tumor response of superselective chemoembolization using calibrated gelatin sponge particles and calibrated microspheres as embolic materials. There is no significant difference in tumor response between the use of calibrated gelatin sponge particles and calibrated microspheres for conventional chemoembolization in small HCC.